Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
06/2003
06/26/2003WO2003051841A2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051840A1 Pyrrolidine and piperidine derivates as nk1 antagonists
06/26/2003WO2003051836A1 Prodrugs to d-prolines
06/26/2003WO2003051833A2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
06/26/2003WO2003051828A2 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
06/26/2003WO2003051826A1 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
06/26/2003WO2003051825A1 Human adam-10 inhibitors
06/26/2003WO2003051822A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003WO2003051821A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003WO2003051819A1 Substituted 1,5-diaminopentan-3-ol compounds
06/26/2003WO2003051807A2 Improvements in pharmaceutical compositions
06/26/2003WO2003051805A2 Substituted phenyl naphthalenes as estrogenic agents
06/26/2003WO2003051458A1 Superoxide dismutase mimics for the treatment of ocular disorders and diseases
06/26/2003WO2003051391A1 Method of treating obesity, overweight, diabetes, or fluctuations in blood insuline or glucose levels
06/26/2003WO2003051389A2 Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
06/26/2003WO2003051386A1 Glucoset agonists and antagonists for use in the treatment of metabolic disorders
06/26/2003WO2003051373A1 Liquid bisphosphonate formulations for bone disorders
06/26/2003WO2003051372A1 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
06/26/2003WO2003051357A1 Glucagon receptor antagonists/inverse agonists
06/26/2003WO2003051333A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/26/2003WO2003051328A1 Solid dose micro implant
06/26/2003WO2003051315A2 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
06/26/2003WO2003051307A2 Materials and methods for the treatment or prevention of obesity
06/26/2003WO2003051293A2 Antidiabetic formulation and method
06/26/2003WO2003051287A2 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003WO2003051277A2 Novel compounds
06/26/2003WO2003051182A2 Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia
06/26/2003WO2003035678A3 Sperm factor sequences
06/26/2003WO2002094202A3 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
06/26/2003WO2002058733A3 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
06/26/2003US20030120074 Cardioprotective phosphonates and malonates
06/26/2003US20030120059 Cell surface molecule-induced macrophage activation
06/26/2003US20030119913 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
06/26/2003US20030119854 Compounds and methods for modulating CXCR3 function
06/26/2003US20030119842 Salts of bicyclic, N-acylated imidazo-3-amines and imidazo-5-amines
06/26/2003US20030119840 4-Heteroparyl-1,4-diazabicyclo[3.2.2]nonane, preparation and therapeutic use thereof
06/26/2003US20030119837 Pharmaceutical composition for the treatment of CNS and other disorders
06/26/2003US20030119835 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents
06/26/2003US20030119829 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of PDE7B-mediated diseases and conditions
06/26/2003US20030119827 Peptidyl carbamates; treatments for osteoporosis and autoimmune diseases
06/26/2003US20030119820 Substituted indoles
06/26/2003US20030119800 Administering an ANGELS (Activators of Non-Genotropic Estrogen-like Signaling compound"ANGELS") compound to maintain or increase bone mass, bone density and/or bone strength.
06/26/2003US20030119795 Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
06/26/2003US20030119788 N-cyanomethyl carbonamides and sulfonamides which are cysteine protease, particularly cathepsin K, inhibitors
06/26/2003US20030119786 Combinations for the treatment of immunoinflammatory disorders
06/26/2003US20030119766 Antisense modulation of apolipoprotein (A) expression
06/26/2003US20030119758 An amine salt of (1-O-(4-(3,4-dimethoxyphenyl)-2-(3-ethylpentanoyl)-5,6,7-trimethoxy-3 -(methoxycarbonyl)naphthalen - 1-yl)-beta-D-glucopyranoside)uronic acid.
06/26/2003US20030119744 Treatment with Prostate Secretory Protein-94 led to a near normalization of plasma calcium and a marked reduction in PTHrP production
06/26/2003US20030119734 GLP-1(7-37) or an analogue wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer; pH is 7-10
06/26/2003US20030119715 Prevent retinoid binding; antiaging agents; activation cell differentiation
06/26/2003US20030119111 G-protein coupled receptor, named 2871 receptor
06/26/2003US20030119095 Novel nucleic acid sequences encoding human vesicle transport protein-like and residue rat-like polypeptides
06/26/2003US20030119076 B7-like polynucleotides, polypeptides, and antibodies
06/26/2003US20030119045 Controlling cell proliferation; adjust adhesion to substrate
06/26/2003US20030119036 Isolated nucleic acids; anticholesterol agents, cardiovascular disorders, antiinflammatory agents, antilipemic agents
06/26/2003US20030118672 Administering a stabilized rice bran derivative and a fortification agent; treating bone disorders
06/26/2003US20030118610 Oral delivery of peptides using enzyme-cleavable membrane translocators
06/26/2003US20030118594 Stable formulations of mhc-peptide complexes
06/26/2003US20030118575 Administering a pyrazole compound containing urea or thiourea groups, twice daily to a patient in need of treatment of a cytokine mediated disease
06/26/2003US20030118536 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003US20030118513 Lung administering; bioavailability
06/26/2003US20030118510 Immobilization of insulin; antidiabetic agents
06/26/2003US20030118507 Methods of using 46828, a human acyl-CoA synthetase
06/26/2003CA2473938A1 Human adam-10 inhibitors
06/26/2003CA2471777A1 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003CA2471500A1 Substituted 1,5-diaminopentan-3-ol compounds
06/26/2003CA2470723A1 3,4-dihydro-1h-isoquinolin-2-yl-derivatives
06/26/2003CA2470491A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003CA2470431A1 Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia
06/26/2003CA2470311A1 Method of screening compounds
06/26/2003CA2470060A1 Improvements in pharmaceutical compositions
06/26/2003CA2469976A1 Improvements in pharmaceutical compositions
06/26/2003CA2469950A1 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
06/26/2003CA2469786A1 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
06/26/2003CA2469302A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003CA2469048A1 Quinolinones as prostaglandin receptor ligands
06/26/2003CA2468687A1 Liquid bisphosphonate formulations for bone disorders
06/26/2003CA2468413A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003CA2467780A1 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors
06/26/2003CA2465888A1 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003CA2446292A1 Nucleic acid-associated proteins
06/25/2003EP1321516A2 Hydrogel matrix for cellular tissue storage
06/25/2003EP1321143A1 Combination of N-butyldeoxygalactonojirimycin and glycolipid degrading enzyme in therapy
06/25/2003EP1320623A1 Promoter sequences
06/25/2003EP1320614A2 Novel proteases
06/25/2003EP1320601A1 Human and rat pgc-3, ppar-gamma coactivations and splice variants thereof
06/25/2003EP1320600A1 Transporters and ion channels
06/25/2003EP1320599A2 Pd-l2 molecules: pd-1 ligands and uses therefor
06/25/2003EP1320550A2 G-protein coupled receptors
06/25/2003EP1320548A2 Transporters and ion channels
06/25/2003EP1320536A1 $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES
06/25/2003EP1320530A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
06/25/2003EP1320523A2 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
06/25/2003EP1320521A1 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(en)oic acid as therapeutic agents
06/25/2003EP1320378A2 Improved protocol for paracentesis
06/25/2003EP1320372A1 Pharmaceutical preparation and method for treatment of diabetes
06/25/2003EP1320371A2 Charged phospholipid compositions and methods for their use
06/25/2003EP1320366A1 Substituted piperidines as melanocortin receptor agonists
06/25/2003EP1320365A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor
06/25/2003EP1320364A1 The use of histamine h3-receptor inverse agonists for the control of appetite and treatment of obesity
1 ... 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 ... 1298